August 23, 2017 09:27 AM Eastern Daylight Time
CRANBURY, N.J.--Physicians’ Education Resource® (PER®) will conduct three CME-Accredited Satellite Symposia during the American Society of Hematology’s 59th Annual Meeting & Exposition (ASH) to be held at the Georgia World Congress Center in Atlanta on Dec. 8. The programs will focus on some of the most pressing issues in hematology. In addition, an internationally renowned expert faculty will be on-site to discuss the latest data and innovations coming out of the annual hematology conference.
“We are thrilled to host the upcoming satellite symposia, which encompass some of the most important topics that will be discussed during this year’s American Society of Hematology’s annual meeting. The three unique programs offered will help familiarize medical professionals with emerging treatments and research in hematology,” said Phil Talamo, president of PER®.
The PER® satellite symposia are as follows:
- Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh In on Recent Data and Clinical Experience, will be held from 1:30 to 4:30 p.m. David Maloney, M.D., Ph.D., event chair and professor of medicine, Division of Oncology at the University of Washington, will discuss key topics including scientific principles underlying the use of CAR T cells in cancer therapy, current applications of CAR T-cell lymphoid malignancies, and proactive methods to mitigate and manage adverse events. To register, click gotoper.com/go/ASH17CART.
- Addressing Post-Transplant Obstacles: Current and Emerging Strategies to Evolve the Standard of Care for Patients with GvHD, will take place from 1:30 to 4:30 p.m. The symposia will be chaired by John F. DiPersio, M.D., Ph.D., deputy director of Siteman Cancer Center at Washington University School of Medicine. This event with highlight topics such as graft-versus-host disease (GvHD) pathogenesis and the evidence that informs best clinical practices to manage GvHD, review current and prophylactic treatment regimens for GvHD, and review current and prophylactic treatment regimens for GvHD. To register, click gotoper.com/go/ASH17GvHD.
- Evaluating the Emerging Role of Biosimilar Agents for the Treatment of Hematologic Malignancies will take place from 7-10 p.m. and will be chaired by Edward Li, PharmD MOH, BCOP, professor in Department of Pharmacy Practice at the University of New England College of Pharmacy. He will offer insight on topics including regulatory process associated with the approval of biosimilars by the U.S. Food and Drug Administration, along with current and emerging efficacy and safety data for biosimilar agents for the treatment of hematologic malignancies. To register, click gotoper.com/go/ASH17BIOSIM.
About PER®:
Since 1995, PER® has been the leading provider of live, online and print CME activities focusing on oncology and hematology by providing high-quality, evidence-based activities featuring leading experts who focus on the application of practice-changing advances. In 2017, PER® will develop and implement 21 historic annual legacy conferences in the Unites States and Europe, along with many world-renowned online learning formats. PER® is also the publisher of the monthly peer-reviewed American Journal of Hematology/Oncology®, is accredited by Accreditation Council for Continuing Medical Education and the California Board of Registered Nursing and is part of the Cranbury, New Jersey-based Michael J. Hennessy Associates, Inc. family of businesses. Learn more at www.gotoper.com and www.mjhassoc.com.
Contacts
PER® Media:
Theresa Burek
[email protected]
or
Surabhi Verma
[email protected]
